Whalesbook
### Brokerage Flags Growth Hurdles
JM Financial initiated coverage on Mankind Pharma with a 'Reduce' rating, signaling caution for investors. The brokerage cited moderating growth in the company's core Indian operations, a significant portion of its revenue, as a primary concern. Analysts believe the company's reliance on mature therapies limits its potential for a substantial recovery solely from its current product mix. Despite management optimism, achieving double-digit growth moving forward appears challenging, according to the report. Mankind Pharma's stock currently trades at a premium compared to its peers, with forward EV/Ebitda multiples around 23x and 20x for FY27 and FY28 respectively, a stark contrast to a forward P/E of approximately 35-40x based on current market data.
### BSV Acquisition Under Scrutiny
The recent acquisition of BSV has drawn particular attention from JM Financial. While it expands Mankind Pharma's presence in women's healthcare and infertility segments, the brokerage views the acquisition price as steep. This valuation is expected to dilute the company's return on capital (RoC), potentially pushing it lower. BSV, while a quality asset, is projected to deliver moderate growth that may not fully justify the premium valuation, potentially leading to a longer payback period. The acquisition is estimated to drag RoC from the high-20 per cent range down to 8-10 per cent during FY26E–FY28E, placing Mankind’s operating and financial metrics below industry peers.
### Valuation Premium and Target Price
Mankind Pharma currently trades at a significant premium to its peers. For instance, Torrent Pharma trades at a forward P/E of approximately 30-35x, Sun Pharma at 25-30x, and Cipla at 20-25x. This premium, coupled with the growth concerns and the impact of the BSV acquisition, has led JM Financial to value the company at 20 times FY28E Ebitda. Consequently, a target price of ₹2,030 has been set, implying potential downside from current trading levels. This valuation contrasts sharply with the general analyst consensus which has historically favored the stock, though JM's view highlights a more critical assessment of future earnings quality.
### Outlook and Export Potential
While Mankind Pharma's chronic therapy portfolio shows resilience, it is insufficient to counteract a slowdown in acute segments. The company's product launch pipeline also offers limited visibility. Exports are identified as a potential growth driver, with an expected 14% compound annual growth rate over FY26-FY28, supported by the BSV business and an expanding US presence. However, projected revenue and EBITDA growth rates of 12% and 14% respectively, are tempered by the expected dip in RoC to 8-10% during FY26-FY28, driven by the costly BSV integration. The Indian pharmaceutical sector itself is expected to grow at a CAGR of 8-10%, presenting a competitive environment where differentiation and efficient capital allocation are paramount. The brokerage projects revenue, Ebitda, and PAT to grow at CAGRs of 12 per cent, 14 per cent and 8 per cent, respectively, over FY25–FY28E, supported by an 88 bps margin expansion from operating leverage, though this is overshadowed by the RoC concerns.